ADMA Biologics (ADMA) CEO Adam Grossman granted RSUs and 444,711 options

Rhea-AI Filing Summary

ADMA Biologics President and CEO Adam S. Grossman reported new equity awards. On February 9, 2026, he acquired 282,529 shares of common stock in the form of restricted stock units granted at $0 and 444,711 stock options with a $16.37 exercise price.

The RSUs vest quarterly over four years under ADMA’s 2022 Equity Compensation Plan, subject to his continued service. The options also vest over four years, with 25% vesting on the one‑year anniversary and the remaining 75% vesting monthly until fully vested on February 9, 2030. After these awards, he directly beneficially owns 2,290,379 shares of common stock and also has indirect ownership of additional ADMA shares through Areth, LLC and Hariden, LLC.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grossman Adam S

(Last) (First) (Middle)

C/O ADMA BIOLOGICS, INC.

465 STATE ROUTE 17

(Street)

RAMSEY NJ 07446

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		A		282,529(1)	A	$0	2,290,379(2)(3)(4)	D
Common Stock								1,143,426	I	See Footnote(5)
Common Stock								580,957	I	See Footnote(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16.37	02/09/2026		A		444,711		(7)	02/09/2036	Common Stock	444,711	$0	444,711	D

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the Reporting Person's continued service as of the applicable vesting date.

2. Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

3. (continued from footnote 3) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

4. (continued from footnote 4) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 975,684 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

5. These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.

6. These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.

7. The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 9, 2030 in accordance with the Plan.

	/s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did ADMA (ADMA) CEO Adam Grossman receive on February 9, 2026?

Adam Grossman received a grant of 282,529 restricted stock units and 444,711 stock options on February 9, 2026. The RSUs are settled in common stock upon vesting, while the options give him the right to buy ADMA common shares at $16.37 each.

How do Adam Grossman’s new ADMA (ADMA) RSUs vest over time?

The 282,529 RSUs granted to Adam Grossman vest quarterly over four years. Vesting occurs on each annual anniversary of the grant date, contingent on his continued service, and each vested installment is settled into ADMA common stock under the 2022 Equity Compensation Plan.

What is the vesting schedule for Adam Grossman’s new ADMA (ADMA) stock options?

Grossman’s 444,711 stock options vest over four years and become fully vested by February 9, 2030. Twenty‑five percent vests on the one‑year anniversary of grant, with the remaining 75% vesting in equal monthly installments over the following three years.

What are Adam Grossman’s direct and indirect ADMA (ADMA) share holdings after the reported grants?

After the reported equity awards, Adam Grossman directly beneficially owns 2,290,379 shares of ADMA common stock. He also has indirect ownership of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC, as disclosed in the footnotes.

Are Adam Grossman’s ADMA (ADMA) equity grants open‑market purchases?

No, the filing classifies the transactions as grants or awards, not market purchases. The Form 4 uses transaction code “A” for acquisitions, indicating equity compensation awards of RSUs and stock options granted at a $0 price rather than shares bought in the open market.

Under which plan were Adam Grossman’s new ADMA (ADMA) RSUs and options granted?

The RSUs and stock options were granted under the ADMA Biologics, Inc. 2022 Equity Compensation Plan. This plan governs vesting terms, including quarterly RSU vesting over four years and option vesting through an initial one‑year cliff followed by monthly vesting to 2030.